1-(2-萘基)-1H-吡唑-4-甲醛 | 518023-77-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 1-(2-萘基)-1H-吡唑-4-甲醛
• 英文名称: 1-(2-Naphthyl)-1H-pyrazole-4-carbaldehyde
• 英文别名: 1-naphthalen-2-ylpyrazole-4-carbaldehyde
• CAS: 518023-77-3
• 化学式: C₁₄H₁₀N₂O
• 分子量: 222.24
• InChiKey: ZQTOQSZEFKUAKA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  34.9
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933199090

文献信息

• [EN] TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE<br/>[FR] INHIBITEURS, À BASE DE TRIAZOLOPYRIDINE, DE LA MYÉLOPEROXYDASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2017040449A1

  公开（公告）日：2017-03-09

  The present invention provides compounds of Formula (I): wherein A is as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.

  本发明提供了化合物的结构式（I）：其中A如规范中定义，并包括任何此类新化合物的组合物。这些化合物是髓过氧化物酶（MPO）抑制剂和/或嗜酸性粒细胞过氧化物酶（EPX）抑制剂，可用作药物。
• NOVEL COMPOUND AS MTOR INHIBITOR AND USE THEREOF
  申请人：Medicinal Bioconvergence Research Center

  公开号：EP3786163A1

  公开（公告）日：2021-03-03

  The present invention relates to a novel compound as an mTOR inhibitor and a use thereof and, more specifically, to a novel compound represented by formula 1 that exhibits mTOR inhibitory activity and a pharmaceutical composition comprising same as an active ingredient for preventing or treating brain diseases associated with an mTOR pathway.

  本发明涉及一种作为mTOR抑制剂的新化合物及其用途，更具体地，涉及一种由式1表示的新化合物，该化合物表现出mTOR抑制活性，并且包括该化合物作为活性成分的药物组合物，用于预防或治疗与mTOR途径相关的脑疾病。
• Triazolopyridine inhibitors of myeloperoxidase
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US10407422B2

  公开（公告）日：2019-09-10

  The present invention provides compounds of Formula (I): wherein A is as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.

  本发明提供了式(I)化合物：其中A如说明书中所定义，以及包含任何此类新型化合物的组合物。 这些化合物是髓过氧化物酶（MPO）抑制剂和/或嗜酸性粒细胞过氧化物酶（EPX）抑制剂，可用作药物。
• TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20190023701A1

  公开（公告）日：2019-01-24

  The present invention provides compounds of Formula (I): wherein A is as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.
• NOVEL COMPOUND AS mTOR INHIBITOR AND USE THEREOF
  申请人：MEDICINAL BIOCONVERGENCE RESEARCH CENTER

  公开号：US20210292314A1

  公开（公告）日：2021-09-23

  The present invention relates to a novel compound as an mTOR inhibitor and a use thereof and, more specifically, to a novel compound represented by formula 1 that exhibits mTOR inhibitory activity and a pharmaceutical composition comprising same as an active ingredient for preventing or treating brain diseases associated with an mTOR pathway.